Clinical Trial Update: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/Phase 2 clinical trial evaluating GV20-0251 as monotherapy and in combination with pembrolizumab in several solid tumor cancers;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Cutaneous Melanoma
• Endometrial Carcinoma
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• GV20-0251
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: GV20 Therapeutics | Conditions: Solid Tumor, Adult, Refractory Cancer | Phase 1, Phase 2 | Status: RECRUITING